Shorter recurrence-free survival was associated with high DDX21 (HR: 1.961, 95% CI: 1.219–3.153, p=0.005), larger tumor size (HR: 1.825, 95% CI: 1.139–2.925, p=0.012), and advanced BCLC stage (HR: 3.676, 95% CI: 2.626–5.974, p < 0.001; Table 3). The gene discussed is DDX21; the disease is neoplasm.